Neumora Therapeutics (NMRA) Share-based Compensation (2022 - 2026)

Neumora Therapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $7.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 20.58% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $28.0 million (down 61.19% YoY), while the FY2025 annual figure was $35.0 million, down 12.48% from the prior year.
• Share-based Compensation for Q1 2026 stood at $7.4 million, roughly flat from $7.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $40.0 million in Q4 2024, with the low at $2.1 million in Q3 2022.
• The 5-year median for Share-based Compensation is $7.3 million (2024), against an average of $8.8 million.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 560.88% in 2024, then tumbled 81.48% in 2025.
• Neumora Therapeutics' Share-based Compensation stood at $2.8 million in 2022, then surged by 116.73% to $6.1 million in 2023, then surged by 560.88% to $40.0 million in 2024, then sank by 81.48% to $7.4 million in 2025, then dropped by 0.03% to $7.4 million in 2026.
• Business Quant data shows NMRA's Share-based Compensation at $7.4 million in Q1 2026, $7.4 million in Q4 2025, and $6.0 million in Q3 2025.